Skip to main content

Featured

Intel’s Weak Earnings Put Futures on Ice After a Choppy Week

U.S. stock futures lost momentum Friday morning as Wall Street tried to steady itself after several days of sharp swings. Dow futures slipped, while S&P 500 and Nasdaq futures hovered slightly lower, signaling a cautious start to the trading day. The hesitation came largely from Intel’s disappointing earnings report. The chipmaker’s results and weaker outlook weighed heavily on tech sentiment, sending its shares sharply lower in pre‑market trading. Investors had hoped for stronger numbers given the industry’s AI‑driven momentum, but Intel’s update suggested ongoing challenges in key segments like data‑center chips. The broader market has been wrestling with volatility all week, driven by shifting economic expectations and uneven corporate results. With the S&P 500 on track for another weekly decline, traders appear reluctant to make big moves until they see clearer signs of stability.
Post a Comment
Read more

article

Labels

Health Canada authorizes updated Pfizer-BioNTech COVID vaccine


Health Canada has authorized Pfizer-BioNTech’s updated COVID-19 vaccine for people six months and older.

The mRNA vaccine targets the Omicron XBB.1.5 subvariant that is circulating in Canada.

This is the second vaccine targeting XBB.1.5 that will be available in this country.

Earlier this month, Health Canada authorized Moderna's updated mRNA vaccine.

Both Pfizer and Moderna's shots are one-dose vaccines for people five years of age and older.

Three shots of the Pfizer vaccine is recommended for children between six months and four years of age who have not received their primary series of a COVID-19 vaccine.

Health Canada says it is currently reviewing an updated non-mRNA vaccine from Novavax.

Novavax’s vaccine has been submitted for consideration for people age 12 years and older.

Labels:

Comments

Post a Comment